SparingVision raises €44.5m for retinitis pigmentosa gene therapyFrench biotech SparingVision has raised 44.5 million euros ($52.7 million) to develop its gene therapy for a rare Share XSparingVision raises €44.5m for retinitis pigmentosa gene therapyhttps://pharmaphorum.com/news/sparingvision-raises-44-5-million-euros-for-retinitis-pigmentosa-gene-therapy/
Sanofi preps trials of second COVID-19 shot, as Russia approves anotherSanofi will shortly start human trials of a second coronavirus vaccine, developed with US biotech Translate Bio, after Share XSanofi preps trials of second COVID-19 shot, as Russia approves anotherhttps://pharmaphorum.com/news/sanofi-preps-trials-of-second-covid-19-shot-as-russia-approves-another/
Sanofi/Regeneron’s Libtayo set for new skin cancer useSanofi and Regeneron plan to file their cancer immunotherapy Libtayo (cemiplimab) in a new indication following supportive findings Share XSanofi/Regeneron’s Libtayo set for new skin cancer usehttps://pharmaphorum.com/news/sanofi-regenerons-libtayo-set-for-new-skin-cancer-use/
Roche’s Actemra cuts chances of COVID-19 ventilator use in phase 3 trialRoche’s Actemra may help fight pandemic after all with phase 3 trial results showing it cut the chances Share XRoche’s Actemra cuts chances of COVID-19 ventilator use in phase 3 trialhttps://pharmaphorum.com/news/roche-actemra-cuts-chances-of-covid-19/
Health2Sync and Sanofi to digitally manage diabetes in TaiwanTaiwan-based digital health firm Health2Sync has partnered with Sanofi to help patients manage symptoms of diabetes. While Sanofi Share XHealth2Sync and Sanofi to digitally manage diabetes in Taiwanhttps://pharmaphorum.com/news/health2sync-and-sanofi-to-digitally-manage-diabetes-in-taiwan/
AZ halts COVID-19 vaccine after safety scare, as UK faces ‘second wave’It’s a bleak day in the fight against COVID-19, after the UK banned social gatherings of more than Share XAZ halts COVID-19 vaccine after safety scare, as UK faces ‘second wave’https://pharmaphorum.com/news/az-halts-covid-19-vaccine-after-safety-scare-as-uk-faces-second-wave/
After a nay from NICE, Scotland says aye to J&J’s SpravatoNHS patients with treatment-resistant depression in Scotland will be able to access Johnson & Johnson’s Spravato, a drug Share XAfter a nay from NICE, Scotland says aye to J&J’s Spravatohttps://pharmaphorum.com/news/after-a-nay-from-nice-scotland-says-aye-to-jjs-spravato/
Sanofi and GSK begin clinical trials of coronavirus vaccineSanofi and GlaxoSmithKline have begun clinical trials of their coronavirus vaccine, as AstraZeneca expanded studies of its rival Share XSanofi and GSK begin clinical trials of coronavirus vaccinehttps://pharmaphorum.com/news/sanofi-and-gsk-begin-clinical-trials-of/
Sanofi/Regeneron’s Kevzara fails again in serious COVID-19 casesSanofi has drawn another blank in its attempt to repurpose its IL-6 drug Kevzara to tackle the extreme Share XSanofi/Regeneron’s Kevzara fails again in serious COVID-19 caseshttps://pharmaphorum.com/news/sanofi-regenerons-kevzara-fails-again-in-serious-covid-19-cases/
